Syk kinase as a treatment target for therapy in autoimmune diseases
- 30 September 2007
- journal article
- editorial
- Published by Elsevier BV in Clinical Immunology
- Vol. 124 (3), 235-237
- https://doi.org/10.1016/j.clim.2007.06.005
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitorClinical Immunology, 2007
- Tumor Necrosis Factor Inhibitors for Rheumatoid ArthritisNew England Journal of Medicine, 2006
- Role of ITAM‐containing adapter proteins and their receptors in the immune system and boneImmunological Reviews, 2005
- Src and Syk kinases: key regulators of phagocytic cell activationTrends in Immunology, 2005
- Progressive Loss of Syk and Abnormal Proliferation in Breast Cancer CellsCancer Research, 2004
- The immunomodulatory adapter proteins DAP12 and Fc receptor γ-chain (FcRγ) regulate development of functional osteoclasts through the Syk tyrosine kinaseProceedings of the National Academy of Sciences, 2004
- Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer.2003
- Imatinib Mesylate — A New Oral Targeted TherapyNew England Journal of Medicine, 2002
- Fc? receptor type I ? chain replaces the deficient T cell receptor ? chain in T cells of patients with systemic lupus erythematosusArthritis & Rheumatism, 2001
- Human spleen tyrosine kinase p72Syk associates with the Src-family kinase p53/56Lyn and a 120-kDa phosphoprotein.Proceedings of the National Academy of Sciences of the United States of America, 1995